期刊
ANALYTICAL CHEMISTRY
卷 90, 期 10, 页码 6307-6313出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.8b01090
关键词
-
资金
- NIH [5R01GM088317, 1R0IGM111788, S10 RR025044]
- NSF [1506752]
- Purdue University Center for Cancer Research [P30 CA023168]
- Division Of Chemistry
- Direct For Mathematical & Physical Scien [1506752] Funding Source: National Science Foundation
Glycoproteins comprise more than half of current FDA-approved protein cancer markers, but the development of new glycoproteins as disease biomarkers has been stagnant. Here we present a pipeline to develop glycoproteins from extracellular vesicles (EVs) through integrating quantitative glycoproteomics with a novel reverse phase glycoprotein array and then apply it to identify novel biomarkers for breast cancer. EV glycoproteomics show promise in circumventing the problems plaguing current serum/plasma glycoproteomics and allowed us to identify hundreds of glycoproteins that have not been identified in blood. We identified 1,453 unique glycopeptides representing 556 glycoproteins in EVs, among which 20 were verified significantly higher in individual breast cancer patients. We further applied a novel glyco-specific reverse phase protein array to quantify a subset of the candidates. Together, this study demonstrates the great potential of this integrated pipeline for biomarker discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据